LSLuchen Shan

Luchen Shan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luchen Shan has a total of 84 co-authors. Here are the top co-authors by number of shared publications:

  • Yuqiang Wang

    Institute of New Drug Research, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, Jinan University College of Pharmacy, Guangzhou, China

    9 shared publications
  • Pei Yu

    State Key Laboratory of Bioactive Molecules and Druggability Assessment, College of Pharmacy, Jinan University, Guangzhou, China

    5 shared publications
  • Jingxiong Luo

    Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio‑cerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, Guangdong 510000, P.R. China

    3 shared publications
  • Liang Wang

    Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China

    3 shared publications
  • Pei Yu

    State Key Laboratory of Bioactive Molecules and Druggability Assessment/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE), College of Pharmacy, Jinan University, Guangzhou, China

    3 shared publications
  • Xiaojing Zhang

    Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, China

    3 shared publications

Latest Publications

  • Open Access

    Editorial: The pharmacological effects and mechanisms of drugs against human diseases by modulating redox homeostasis - volume II

    by Xiaofang Zhang, Ming Xu, Zhihao Liu, Luchen Shan

    The Pharmacological Effects and Mechanisms of Drugs Against Human Diseases by Modulating Redox Homeostasis II Once widely promoted by journal articles, textbooks, and the media for their presumed health benefits, antioxidants are now understood within a more nuanced framework. It is increasingly recognized that oxidants-particularly reactive oxygen species (ROS)-play dual roles as both harmful agents and essential signaling molecules [1] . While excessive ROS can cause oxidative stress and damage to DNA, proteins, and lipids, contributing to various diseases, low to moderate levels are crucial for maintaining normal cellular functions. Reflecting this conceptual shift, the present Research Topic focuses on redox homeostasis modulators rather than narrowly defined antioxidants.The seven original research articles and two literature reviews published in this Research Topic illustrate the evolving conceptual framework from three distinct perspectives:Inhibiting ROS overproduction and accumulation confers tissue protection. Mao et al. demonstrated that acrolein-an environmental pollutant and a byproduct of lipid peroxidation (a reactive molecule)-induces glutathione (GSH) depletion, triggering Sertoli cell ferroptosis and lipid peroxidation, ultimately leading to male reproductive toxicity and cyclophosphamide (a precursor of acrolein)-induced cystitis [3,4] . Enhancing endogenous hydrogen sulfide (H2S) production or administering exogenous H₂S counteracts this process by directly neutralizing acrolein to restore glutathione levels and suppress oxidative signaling. Another study by Zhu et al. demonstrated that gallic acid mitigates intervertebral disc degeneration by upregulating the antioxidant enzyme GPX2 and the transcription factor NRF2 (coordinating the cellular antioxidant response) while reducing levels of 4-hydroxynonenal-a byproduct of lipid peroxidation-and mitochondrial iron deposition [5] . Lu et al. revealed that D-mannose enhances antioxidant defenses in ulcerative colitis models by increasing the levels of superoxide dismutase and glutathione while reducing malondialdehyde, a marker of lipid peroxidation [6] . In a related study, Yan et al. reported that dl-3-n-butylphthalide disrupts Keap1-Nrf2 complex formation, thereby preventing Nrf2 ubiquitination, promoting the expression of antioxidant genes, reducing mitochondrial ROS, and ultimately improving cardiac function in a mouse model of doxorubicin-induced cardiotoxicity [7] .Hao and colleagues documented a notable finding: quercetin-encapsulated PEG-PCL micelles (Que-PEG-PCL) significantly attenuate cisplatin-induced nephrotoxicity, reducing serum creatinine and blood urea nitrogen (BUN) levels to 42% and 38%, respectively [8] . This protective effect is attributed to a reduction in oxidative stress and an enhancement of antioxidant activity.Furthermore, co-administration with Que-PEG-PCL increased cisplatin plasma exposure to 323% while decreasing renal clearance to 14%, likely through inhibition of the organic cation transporter 2 (OCT2). In a CT26 syngeneic tumor model, this combination therapy suppressed tumor volume by 84% compared to the control group.Leveraging ROS generation enables precision therapies. Pang et al. showed that the iridium(III) complex Ir-1 enhances lung cancer radiosensitivity by increasing intracellular ROS, disrupting mitochondrial membrane potential, and activating the Bax/Bak-cytochrome c-caspase-9 apoptotic pathway, leading to G2/M arrest and apoptosis with minimal toxicity to normal fibroblasts [9].Similarly, the nanocarrier Que-PEG-PCL boosts cisplatin's pro-oxidant effects in CT26 colon cancer, synergistically increasing ROS, triggering mitochondrial depolarization, and inducing apoptosis-achieving 84% tumor suppression, far surpassing free quercetin or cisplatin alone.Together, these strategies illustrate the "double-edged sword" of redox modulation: using ROS to selectively eliminate tumors while sparing healthy tissue.in this collection present new findings on the context-dependent benefits of both antioxidants and pro-oxidants, two accompanying review articles offer a broader and more comprehensive perspective on antioxidants derived from natural sources. Zhang et al. synthesized current knowledge on the antioxidative properties and therapeutic effects of flavonoids in mitigating vasospasm associated with myocardial and cerebral infarction [10] . Meanwhile, Wei et al. focused on curcumin, highlighting its dual role in scavenging free radicals and suppressing NF-κB signaling in models of Alzheimer's disease and dopaminergic neuron loss in Parkinson's disease [11] .supporting the rationale and therapeutic potential of both antioxidants and pro-oxidants as modulators of redox homeostasis. However, the current studies primarily focus on the isolated effects of these agents, rather than addressing the broader and more critical challenge: the establishment, restoration, and long-term maintenance of redox balance.The clinical efficacy of antioxidants continues to be a subject of intense debate, with studies yielding conflicting results across both experimental and real-world settings. This ongoing controversy arises from a complex web of biological variability, methodological limitations, and the dual-sometimes paradoxical-roles of reactive oxygen species (ROS) in both physiology and pathology.To what extent should ROS be reduced or enhanced to confer therapeutic benefit? While, in theory, redox homeostasis can be quantified using molecular markers and redox couples that reflect the balance between oxidizing and reducing species in cells, tissues, or fluids, the practical application of this concept is fraught with challenges.The inherent complexity of biological systems, the transient nature of redox reactions, and the highly context-dependent behavior of both oxidants and antioxidants complicate efforts to measure and modulate redox states precisely.The efficacy of antioxidants...

  • Inhibition of Cathepsin B Ameliorates Murine Cognitive Dysfunction and Neuronal Damage in Ischemic Stroke by Inhibiting Mitochondrial Apoptosis and Drp1-Mediated Mitochondrial Fission

    by Hongyi Jia, Bingge Zhang, Xiao Han, Pei Yu, Bocheng Xiong, Tiansu Liu, Luchen Shan, Xifei Yang, Qinghua Hou

    The surviving brain tissue undergoes secondary degeneration long after an ischemic stroke. Cathepsin B plays dual roles as both a scavenger and an executor. Using a mouse model of ischemic stroke, we specifically investigated the mechanism by which inhibiting Cathepsin B with CA074 methyl ester (CA-074Me) during the chronic phase of stroke exerts a protective effect. In the intervention group, CA-074Me (20 μg CA-074Me/1 μl DMSO) was stereotaxically injected in the right ventricle, and, 30 min later, the animals were subjected to develop transient middle cerebral artery occlusion and reperfusion (tMCAO/R) stroke model with modified Longa method. In the model group, 1 μl DMSO was given in the right ventricle instead and the sham-operated group received 1 μl DMSO in the right ventricle without arterial occlusion. We evaluated the effects of inhibition of Cathepsin B on the nervous system after tMCAO/R injury by combined use behavioral tests, neurological deficit scoring, Western blot and other pharmacological methods and explored the underlying mechanism. After tMCAO/R, sustained upregulation and activation of Cathepsin B was noticed in the ipsilateral hippocampus CA1 zone and CA-074Me ameliorated the parallel lysosome-mitochondria damage, decreased apoptosis, improved the cognitive dysfunction, but had no effects on levels of mouse anxiety or depression. Furthermore, CA-074Me reduced neuroinflammation, levels of oxidative stress and mitochondria fission. Inhibition of Cathepsin B alleviates mitochondrial abnormalities in the ipsilateral hippocampus CA1 zone 28 days after tMCAO/R by suppressing Drp-1mediated excessive mitochondrial fission. This, in turn, reduces neuronal apoptosis, ameliorates neuroinflammation, and mitigates oxidative stress and neuronal damage, indicating Cathepsin B may serve as a potential therapeutic target for remote secondary degeneration following acute ischemic stroke.


  • Synthesis and biological evaluation of novel isobenzofuran-1(3H)-one derivatives as antidepressant agents

    by Liu Tao, Chuanjie Yao, Sijie Wang, Yuying Ye, Zhengchao Tu, Xiaojian Jiang, Lipeng Xu, Luchen Shan, Zheng Liu, Pei Yu


  • Apigenin promotes apoptosis of 4T1 cells through PI3K/AKT/Nrf2 pathway and improves tumor immune microenvironment in vivo

    by Chu Zhang, Yupei Liao, Tangjia Li, Haijing Zhong, Luchen Shan, Pei Yu, Chenglai Xia, Lipeng Xu

    The 2022 US Cancer Statistics show that breast cancer is one of the most common cancers in women. Epidemiology has shown that adding flavonoids to the diet inhibits cancers that arise in particular women, such as cervical cancer, ovarian cancer, and breast cancer. Although there have been research reports on apigenin (API) and breast cancer, its anti-tumor effect and potential mechanism on breast cancer have not yet been clarified. Therefore, in this study, we used 4T1 cells and a 4T1 xenograft tumor mouse model to investigate the antitumor effect of API on breast cancer and its underlying mechanism. In vitro, we used MTT, transwell, staining, and western blotting to investigate the inhibitory effect of apigenin on 4T1 and the underlying molecular mechanism. In vivo by establishing a xenograft tumor model, using immunohistochemistry, and flow cytometry to study the inhibitory effect of apigenin on solid breast tumors and its effect on the tumor immune microenvironment. The results showed that API can induce breast cancer cell apoptosis through the PI3K/AKT/Nrf2 pathway and can improve the tumor immune microenvironment in mice with breast tumors, thereby inhibiting the growth of breast cancer. Thus, API may be a promising agent for breast cancer treatment.


  • Open Access

    Editorial: The pharmacological effects and mechanisms of drugs against human diseases by modulating redox homeostasis

    by Ying Zhang, Luchen Shan, Fuchun Yang, Zhihao Liu, Ming Xu

    Editorial: The pharmacological effects and mechanisms of drugs against human diseases by modulating redox homeostasis

  • iTRAQ-based Proteomics Analysis of ADTM for Preventing the Development of Nitroglycerin-induced Tolerance

    by Luchen Shan, Huihui Hu, Jia Wu, Baojian Guo, Yuqiang Wang

    Background: Long-term nitroglycerin (NTG) therapy causes tolerance, which limits its clinical application. Previous studies have reported a novel Danshensu/tetramethylpyrazine derivative ADTM, which displays strong cardioprotective effects. However, the effect of ADTM is not known in the NTGinduced tolerance model. In this study, we aimed to evaluate the potential improvement and underlying mechanism of ADTM for preventing the development of NTG-induced tolerance in in vivo and in vitro experiments. Methods: Firstly, the effect of ADTM was determined on NTG-induced tolerance using isolated thoracic aortic rings obtained from rats (50 μM for 45 min). After intragastric administration of ADTM (30 mg/kg, twice a day) for 7 days, NTG solution (10 mg/kg) was subcutaneously injected into male Sprague-Dawley (SD) rats once a day for 7 consecutive days. The systolic arterial pressure (SAP), diastolic arterial pressure (DAP), and mean arterial pressure (MAP) were recorded using the PowerLab system. The iTRAQ-based proteomics analysis was used to clarify the underlying mechanism of ADTM in NTG-induced tolerance. Results: ADTM markedly enhanced relaxation sensitivity and vasodilator responses to NTG tolerance in the isolated rat thoracic aorta, and this effect was independent of the vascular endothelium. ADTM prevented the development of NTG-induced tolerance in rats by improving hemodynamic parameters, such as SAP, DAP, and MAP. The iTRAQ-based proteomic analysis suggests that ADTM prevention of NTGinduced tolerance may be related to the regulation of ribosomal metabolism and tight junctions. Conclusion: These results indicate that ADTM has therapeutic potential for NTG-induced tolerance, and is worthy of further studies.


  • Danshensu derivative ADTM ameliorates CCl4‑induced acute liver injury in mice through inhibiting oxidative stress and apoptosis

    by Shu Jia, Qi Chen, Jingyi Wu, Xiaokun Yao, Jingping Shao, Xiaoyan Cheng, Congcong Zhang, Danwei Cen, Yuqiang Wang, Zhihong Shen, et al.


  • Open Access

    A novel danshensu/tetramethypyrazine derivative attenuates oxidative stress‑induced autophagy injury via the AMPK‑mTOR‑Ulk1 signaling pathway in cardiomyocytes

    by Caipeng Xie, Jingxiong Luo, Huihui Hu, Liang Wang, Pei Yu, Lipeng Xu, Yewei Sun, Yuqiang Wang, Luchen Shan

    Myocardial ischemia/reperfusion injury (MIRI) is an inevitable and unsolved clinical problem in the treatment of ischemic heart diseases. Compound DT‑010 is a novel danshensu/tetramethylpyrazine derivative and was examined as a candidate for treating MIRI. In the present study, MTT, lactate dehydrogenase assay and Hoechst staining data indicated that DT‑010 attenuated tert‑butylhydroperoxide (t‑BHP)‑induced oxidative damage by increasing cell survival, reducing cell damage and decreasing apoptosis in H9c2 cardiomyocytes. Autophagy was assessed by western blotting for microtubule‑associated protein 1A/1B‑light chain 3 (LC3‑II and LC3‑I) expression, acridine orange and monodansylcadaverine staining for autophagosome formation and the monomeric red fluorescent protein‑green fluorescent protein‑LC3 assay for autophagic flow. t‑BHP‑induced cell damage was aggravated by the autophagy agonist rapamycin and alleviated by the autophagy blocker hydroxy‑chloroquine, suggesting that autophagy was involved in t‑BHP‑induced cardiomyocyte injury. DT‑010 pretreatment significantly prevented t‑BHP‑induced cell damage, which was partially but significantly abolished by rapamycin and significantly improved by hydroxy‑chloroquine treatment. DT‑010 treatment inhibited t‑BHP‑induced autophagy in H9c2 cells, reduced phosphorylation of 5'‑AMP‑activated protein kinase (AMPK) and promoted the phosphorylation of mTOR and unc‑51 like autophagy activating kinase 1 (Ulk1). To conclude, DT‑010 can serve as a potential candidate for myocardial ischemia‑reperfusion injury therapy. The cardioprotective effects of DT‑010 could be partially attributed to its inhibition of autophagy via the AMPK‑mTOR‑Ulk1 signaling pathway.


  • Open Access

    A Danshensu-Tetramethylpyrazine Conjugate DT-010 Overcomes Multidrug Resistance in Human Breast Cancer

    by Xinhua Zhou, Anqi Wang, Liang Wang, Jianhua Yin, Li Wang, Lijun Di, Maggie Pui-Man Hoi, Luchen Shan, Xu Wu, Yuqiang Wang

    Background: We previously demonstrated that a Danshensu-Tetramethylpyrazine conjugate DT-010 enhanced anticancer effect of doxorubicin (Dox) in Dox-sensitive human breast cancer cells, and protected against Dox-induced cardiotoxicity. This work was designed to see whether DT-010 overcomes Dox resistance in resistant human breast cancer cells. Methods: The effects of DT-010, Dox or their combination on cell viability of Dox-resistant human breast cancer MCF-7/ADR cells were conducted using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis was examined by flow cytometry after Annexin V-FITC/PI co-staining. Dox accumulation in MCF-7/ADR cells was detected by flow cytometry and fluorescence microscopy. A fluorometric multidrug resistance (MDR) assay kit was used to evaluate the effect of DT-010 on MDR transporter activity. P-glycoprotein (P-gp) expression and activity were analyzed by Western blot and rhodamine 123 (Rh123) efflux assay, respectively. The effects of DT-010 on glycolysis and mitochondrial stress were detected using an Extracellular Flux Analyzer. A Succinate Dehydrogenase Activity Assay kit was used to measure mitochondrial complex II activity. Results: At non-cytotoxic concentrations, DT-010 in combination with Dox led to a significant growth inhibition of MCF-7/ADR cells, suggesting a synergy between DT-010 and Dox to reverse Dox resistance. DT-010 restored Dox-mediated apoptosis and p53 induction in MCF-7/ADR cells. DT-010 increased Dox accumulation in MCF-7/ADR cells via inhibiting P-gp activity, but without changing P-gp expression. Further studies showed that DT-010 significantly inhibited glycolysis and mitochondrial function of MCF-7/ADR cells. Mitochondrial complex II activity was inhibited by DT-010 or DT-010/Dox combination, but not by Dox. The DT-010-mediated suppression of metabolic process may render cells more vulnerable to Dox treatment and thus result in enhanced efficacy. Conclusions: The results indicate that DT-010 overcomes Dox resistance in human breast cancer cells through a dual action via simultaneously inhibiting P-gp-mediated drug efflux and influencing metabolic process.